Thomas Bethke

from Wikipedia, the free encyclopedia

Thomas Dieter Bethke (born December 12, 1961 in Uetersen , Schleswig-Holstein) is a German physician, clinical pharmacologist and university professor. Bethke was involved in the development and approval of new drugs such as the proton pump inhibitor pantoprazole , the inhaled steroid ciclesonide and the clinically effective phosphodiesterase (PDE) -4 inhibitor in the chronic obstructive pulmonary disease (COPD) roflumilast .

Bethke studied human medicine at the University Medical Center Hamburg-Eppendorf . In 1989 he received his doctorate with an experimental thesis on inotropic drugs for heart failure . He then spent two years researching cardiovascular topics before specializing in clinical pharmacology. In 1995 he obtained his specialist degree in clinical pharmacology. He gained clinical-practical and scientific experience at the University of Virginia (USA) and Yale University (USA).

Bethke is an adjunct professor at the Medical Faculty of the Eberhard Karls University in Tübingen , specializing in clinical pharmacology.

His research focus is the experimental and clinical pharmacology as well as the therapeutic application of PDE inhibitors. Doctorate (Hamburg 1989) and habilitation (Tübingen 2009) dealt with these topics.

Bethke also completed a Master of Business Administration in economics (Kollegg Graduate School of Management, Northwestern University, Chicago, and Otto Beisheim University of Management, Graduate School of Management, Koblenz 1999; Master's thesis: “ Knowledge Management in Clinical Drug Development”) from.

Bethke held various management positions in the pharmaceutical industry. From 1996 to 2001 he was head of human pharmacology at Byk Gulden , then from 2001 to 2006 international clinical research at Altana Pharma, where he was Vice President for Clinical Development Strategy from 2006/2007, and from 2007 he was Medical Director at Nycomed .

In 2000 he became a Fellow of the Faculty of Pharmaceutical Medicine, London. He is a member of the training commission of the German Society for Pharmaceutical Medicine.

Fonts

  • with DC Grootendorst, SA Gauw, PJ Sterk, JJ Hospers, PS Hiemstra, KF Rabe: 4 weeks treatment with PDE4 inhibitor roflumilast does not change airway inflammation in sputum in patients with COPD. In: Targeting inflammation in asthma and COPD - Interventions beyond inhaled steroids. 149 161, Diana C. Grootendorst, 2003, ISBN 90-6734-207-6 .
  • with H. Tenor, A. Hatzelmann, R. Beume, G. Lahu, K. Zech: Pharmacology, clinical efficacy and tolerability of PDE4 inhibitors: Impact of human pharmacokinetics. In: SH Francis et al. (Ed.): Phosphodiesterases as Drug targets, Handbook of Experimental Pharmacology. Springer-Verlag Berlin Heidelberg, 2011, ISBN 978-3-642-17968-6 .
  • with A. Hatzelmann, R. Beume, C. Schudt, H. Tenor: Significance and potential possibilities of roflumilast as an anti-inflammatory principle. In: OC Burghuber (Hrsg.): Comorbidity in obstructive airways diseases - inflammation and anti-inflammatory therapy. Textbook. UNI-MED Verlag AG, Bremen / London / Boston 2012, ISBN 978-3-8374-2231-3 .

Web links

Individual evidence

  1. Jump up ↑ KF Rabe, ED Bateman, D. O'Donnell, S. Witte, D. Bredenbröker, TD Bethke: Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomized controlled trial. In: The Lancet. No. 366, 2005, pp. 563-571.
  2. ^ Website of the Eberhard-Karls-Universität Tübingen , accessed on March 18, 2012.
  3. ↑ German Society for Pharmaceutical Medicine ( Memento from July 30, 2012 in the web archive archive.today )
personal data
SURNAME Bethke, Thomas
ALTERNATIVE NAMES Bethke, Thomas Dieter (full name)
BRIEF DESCRIPTION German pharmacologist
DATE OF BIRTH December 12, 1961
PLACE OF BIRTH Uetersen , Schleswig-Holstein